<DOC>
	<DOCNO>NCT03044743</DOCNO>
	<brief_summary>This study evaluate safety PD-1 knockout EBV-CTL cell treat EBV ( Epstein-Barr virus ) positive advanced stage malignancy . Blood sample also collect research purpose .</brief_summary>
	<brief_title>PD-1 Knockout EBV-CTLs Advanced Stage Epstein-Barr Virus ( EBV ) Associated Malignancies</brief_title>
	<detailed_description>This study CRISPR-Cas9 mediate PD-1 knockout-T cell autologous origin . Patients assign receive 4 circle cell therapy . The safety clinical response evaluate . Biomarkers immunological marker also monitor .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Nasopharyngeal Neoplasms</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<criteria>Pathologically verify stage IV gastric carcinoma , nasopharyngeal carcinoma lymphoma measurable lesion ( At least one measurable lesion immunotherapy ) Pathologically verify EBV positive malignancy Human leukocyte antigen ( HLA ) genotype : HLAA02 , HLAA24 HLAA11 genotype Progressed standard treatment patient refuse accept standard treatment Performance score : 01 Expected life span : &gt; = 3 month Toxicities prior treatment resolve . Washout period 1 month Major organ function normally Women pregnant age contraception Willing able provide inform consent Patients possible drug allergy immunotherapy Patients active bacterial fungal infection Coagulopathy , ongoing thrombolytic and/or anticoagulation Bloodborne infectious disease , e.g . hepatitis B , hepatitis C HIV History coronary artery disease , asthma , vascular disease disease inappropriate treatment deem treat physician With tumor except situ cervical cancer , treat squamous cell carcinoma bladder cancer ( Ta TIS ) malignancy treat radical therapy ( least 5 year enrollment ) With immune disease , chronic use immunosuppressant steroid Pregnant lactate woman Compliance expect Other condition require exclusion deem physician</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>PD-1</keyword>
	<keyword>CRISPR Cas9</keyword>
	<keyword>EBV</keyword>
	<keyword>advanced stage malignancy</keyword>
</DOC>